Kailera Therapeutics, Inc. (KLRA) Stock Ticker
KLRA right now
Market factors today
Unlock the full KLRA picture
About Kailera Therapeutics, Inc.
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
KLRA stock facts
| Ticker symbol | KLRA |
| Exchange | NASDAQ Global Select |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $1.5B |
| CEO | Ronald C. Renaud Jr. |
| Employees | 145 |
| Headquarters | Waltham, MA, US |
| IPO date | 2026-04-17 |
| Website | www.kailera.com |
What you can see for KLRA on Tickr
Live KLRA price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the KLRA report.
Rankings
FAQ
What is the ticker symbol for Kailera Therapeutics, Inc.?
The ticker symbol for Kailera Therapeutics, Inc. is KLRA, listed on the NASDAQ Global Select.
What is KLRA?
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral…